Rockefeller Capital Management
PTGX icon

Rockefeller Capital Management’s Protagonist Therapeutics PTGX Stock Holding History

Rockefeller Capital Management’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$509K Buy
4,828
+1,536
+47% +$136K ﹤0.01% 1964
2025
Q4 		$288K Buy
3,292
+312
+10% +$25.5K ﹤0.01% 2180
2025
Q3 		$198K Buy
+2,980
New +$169K ﹤0.01% 2240
2020
Q4 		– Sell
-2,000
Closed -$39K – 2983
2020
Q3 		$39K Hold
2,000
– – ﹤0.01% 1587
2020
Q2 		$35K Buy
+2,000
New +$25.1K ﹤0.01% 1506

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Rockefeller Capital Management's PTGX Position: Q1 2026 in Review

Rockefeller Capital Management increased its Protagonist Therapeutics (PTGX) stake by 47% in Q1 2026, buying an estimated $136K and bringing the position to 4,828 shares worth $509K. The position accounts for ﹤0.01% of the portfolio, ranked #1964.

Rockefeller Capital Management first reported a position in PTGX in Q2 2020 and has held it in 5 quarters since. 317 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

  • Rockefeller Capital Management held 4,828 shares of Protagonist Therapeutics worth $509K as of Q1 2026.
  • Rockefeller Capital Management bought 1,536 Protagonist Therapeutics shares in Q1 2026, an estimated $136K.
  • Protagonist Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #1964 holding.
  • Rockefeller Capital Management first reported a position in Protagonist Therapeutics in Q2 2020 and has held it in 5 quarters since.
  • 317 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.